BCL2 and neoplasm: By shedding more light on the complex interplay of BCL-2 family proteins, tumor cell metabolic reprogramming, or tumor microenvironment, we will be able to optimize BCL-2 inhibitor effectiveness by combining these medications with therapies that upregulate proapoptotic proteins and alter cellular metabolism.